In recent years, precision medicine treatment has emerged as a viable option for ICC patients, with the US FDA approving pemigatinib, a second-line ATP-competitive FGFR kinase inhibitor, for the treatment of advanced cholangiocarcinoma specifically featuring fibroblast growth factor receptor 2 (FGFR2) translocation [4]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.